Janssen gains US OK for Simponi Aria in RA

Janssen Biotech, a subsidiary of Johnson and Johnson, won the US FDA's approval on 18 July to market the firm's infusible formulation of golimumab under the brand-name Simponi Aria in combination with methotrexate to treat adults with moderately to severely active rheumatoid arthritis (RA).